CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired VivoPath LLC for $2.3 million (including $1.6 million in contingent consideration), a transaction completed in June 2014, structured as all cash. The deal was a Asset purchase.
VivoPath LLC operates in Discovery and Safety Assessment (DSA) — In Vivo Discovery, is based in United States. VivoPath LLC was a discovery service company specializing in the rapid, in vivo compound evaluation of molecules in the therapeutic areas of metabolism, inflammation and oncology.
In June 2014, the Company acquired substantially all of the assets of VivoPath LLC (VivoPath), a discovery service company specializing in the rapid, in vivo compound evaluation of molecules in the therapeutic areas of metabolism, inflammation and oncology.
In Vivo Discovery business, DSA segment
In June 2014, the Company acquired substantially all of the assets of VivoPath LLC (VivoPath), a discovery service company specializing in the rapid, in vivo compound evaluation of molecules in the therapeutic areas of metabolism, inflammation and oncology. The preliminary purchase price was $2.3 million, including $1.6 million in contingent consideration.Charles River FY2014 10-K, Business Acquisitions note
Advisory firms were not disclosed for this transaction.